SABCS 2020 Immunotherapy In-Depth

Nivolumab-Abemaciclib-Endocrine Therapy Trial Stopped Due to Toxicity

Although the combination was deemed active in HR-positive, HER2-negative disease, findings don’t support further research.

Preoperative Pembrolizumab Plus Radiotherapy Found Active in TNBC

Combining neoadjuvant pembrolizumab with radiotherapy prior to standard of care chemotherapy may increase pathologic complete responses rates in TNBC.

Promising Outcomes With Lenvatinib Plus Pembrolizumab in Advanced TNBC

The majority of responses seen were ongoing at data cutoff.

Oncolytic Virus Primes an Immune Response in Breast Cancer

The oncolytic virus pelareorep may mediate priming of an adaptive immune response in women with early breast cancer.

Immune-Enriched Phenotype Linked to Improved TNBC Survival After AC

Improvements likely due to underlying genomic instability, increased sensitivity to DNA-damaging chemotherapy.

No Benefit to Single-Agent Pembrolizumab in Some With mTNBC Metastasized to Liver or Lung

Women with lung, liver metastases and high PD-L1 expression saw a survival benefit.